Blood clots pose major risks for patients undergoing bladder cancer surgery

In a study of 3879 patients who underwent radical cystectomy to treat bladder cancer, 3.6% were diagnosed with a venous thromboembolism (VTE)—which occurs when a blood clot forms in a vein, potentially breaking loose and traveling to the lung—within 1 month of their surgical admission date. This increased to 4.7% at 2 months and 5.4% at 3 months. Fifty-five percent of VTE events occurred after hospital discharge, generally when patients are not treated prophylactically with drugs to decrease this risk.

There were very few factors found that could predict which patient would suffer from a VTE, other than those with longer length of stay in the hospital. For the first time, this study demonstrated that with VTE tended to die earlier from their .

"Although the findings in this population-based study confirmed some previous understanding of the frequency of VTE for this complex surgery, we were surprised at the number that were diagnosed after ," said Dr. D. Robert Siemens, senior author of the BJU International study. "Furthermore, we were unable to identify strong predictive factors associated with VTE, suggesting to us that most all patients should receive prolonged VTE prophylaxis well beyond their hospital discharge." Dr. Siemens noted that the fact that a VTE was associated with lower cancer cure was also intriguing and suggests that this could represent a marker of more aggressive disease.

More information: R. Christopher Doiron et al. Risk factors and timing of venous thromboembolism after radical cystectomy in routine clinical practice: a population-based study, BJU International (2016). DOI: 10.1111/bju.13443

Provided by Wiley
Citation: Blood clots pose major risks for patients undergoing bladder cancer surgery (2016, March 7) retrieved 18 April 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

ASCO: VTE is risk factor for recurrence in esophageal cancer


Feedback to editors